Lixte Biotechnology Holdings, Inc.

NASDAQ:LIXT

Biotechnology

Healthcare
$7.21 +6.61%

+$0.46 today

Market cap
$89.11M
Beta
1.05
P/E (TTM)
-11.1
EPS (TTM)
-$0.67
52W Low $0.68High $7.78

Volume 0.61M

Average 0.12M

Returns on capital

Lixte Biotechnology Holdings, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-62.2%

avg -290.2%

ROIC

-42.3%

avg -282.2%

ROA

-47.2%

avg -184.4%

Analysis

ROIC is currently the strongest return metric at -42.3% versus its period average of -282.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Geordan G. Pursglove

Chief Executive Officer, President & ChairmanUSD 210K38——

Bastiaan van der Baan

Chief Scientific OfficerUSD 174K54——

Peter Stazzone

Chief Financial OfficerUSD 62K74100.00K0.86%

Compensation is shown in the reported currency; data updated Jun 18, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Lixte Biotechnology Holdings, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

Questions

Management questions

Common questions about LIXT's management, answered from reported figures.

Who manages LIXT?

Lixte Biotechnology Holdings, Inc. (LIXT) lists 3 active executives. The top listed executive is Bastiaan van der Baan, Chief Scientific Officer.

Are LIXT insiders buying or selling?

Recent insider activity shows net buying of $5.72M.